1 / 29

Biological Effects of Pulsed Electromagnetic Field (PEMF) Therapy

Biological Effects of Pulsed Electromagnetic Field (PEMF) Therapy. Keith R. Holden, M.D. Ponte Vedra Beach, FL www.Dr-Holden.com. Objectives. What is PEMF therapy. PEMF as a diagnostic & safe therapeutic tool. Brief history of PEMF therapy. Conditions that respond to PEMF in RDBPC trials.

arne
Download Presentation

Biological Effects of Pulsed Electromagnetic Field (PEMF) Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Biological Effects of Pulsed Electromagnetic Field (PEMF) Therapy Keith R. Holden, M.D. Ponte Vedra Beach, FL www.Dr-Holden.com

  2. Objectives • What is PEMF therapy. • PEMF as a diagnostic & safe therapeutic tool. • Brief history of PEMF therapy. • Conditions that respond to PEMF in RDBPC trials. • Conditions cleared for PEMF therapy by the FDA.

  3. Objectives • Future of PEMF therapy: • Diabetes. • Cardiovascular disease. • Antimicrobial therapy. • Antitumor therapy. • How PEMF promotes bone health & how to monitor response to therapy.

  4. Pulsed Electromagnetic Field (PEMF) Therapy • Time-varying EM fields → microcurrents. • Microcurrents (information) create specific biological responses. • Specific biological responses dependent on field amplitude, frequency, wave form and condition.

  5. PEMF Device Specifications • Frequency range 0.1 – 32,000 Hz • Induced current up to 400 micro Amps • Handheld applicator 55mT • Neck applicator 40mT • Matrix applicator 10mT • Wide Field applicator 0.9mT (dia. 50cm)

  6. PEMF as a Diagnostic Tool • Body contains multiple electromagnetic fields. • Each organ & tissue has a unique electromagnetic signature. • CT & MRI scans take advantage of these unique EM signatures to create tissue maps.

  7. History of PEMF Therapy • 1954 Japanese scientists discovered piezoelectric properties of bone. • Further research showed damaged bone responds therapeutically to PEMF. • 1995 Researchers showed that each soft tissue responds favorably to specific PEMF.

  8. PEMF Therapy in RDBPC Trials • Chronic lower back pain. • Fibromyalgia. • Cervical and knee osteoarthritis. • Lateral epicondylitis. • Recovery from arthroscopic knee surgery. • Persistent rotator cuff tendinitis. • Multiple Sclerosis.

  9. FDA Approved Indications for PEMF • Non-union fractures. • Failed joint fusion following arthrodesis. • Failed spinal fusion. • Congenital pseudoarthrosis. • Postoperative edema & pain in superficial soft tissue. • Refractory Major Depression (rTMS).

  10. Repetitive Transcranial Magnetic Stimulation (rTMS) • Refractory Major Depression (FDA approved). • Schizophrenia. • PTSD. • OCD. • Alzheimer’s disease. • Parkinson’s disease.

  11. Future of PEMF Therapy

  12. Diabetes and PEMF Therapy • Streptozotocin induced diabetic neuropathy. • PEMF tx rats showed decreased BG levels. • Suggests PEMF can ameliorate painful sxs of DM by partially preventing hyperglycemia.

  13. Hyperlipidemia and PEMF Therapy • Hyperlipidemia in rats tx with PEMF 8 weeks. • Lowered blood viscosity. • TC decreased 40.52%. • TG decreased 52.4%. • HDL increased 66.67%. • Fatty material deposition on lining of thoracic aorta significantly lighter in PEMF group.

  14. Cerebral Ischemia & PEMF Therapy • Transient focal cerebral ischemia induced in rats. • PEMF (75 Hz) initiated 10 min after onset. • PEMF continued throughout reperfusion for a total of 6 hours. • PEMF attenuated cortical ischemic edema on MRI by 65%. • Histologic exam showed PEFM reduced ischemic neuronal damage by 69%.

  15. Antimicrobial Effects of PEMF • Staph aureus in fluid medium. • Treated with low-frequency PEMF +AC. • Sig. growth reduction of CFU/ml by 36%. • Application of low-frequency PEMF could theoretically be useful in osteomyelitis.

  16. Biofilms and PEMF Therapy • Applied PEMF 50 Hz to H. pylori biofilms. • PEMF sig ↓ cell viability during early biofilm formation but not mature biofilm. • Sig ↓ biofilm cell mass in both biofilms. • PEMF induces phenotypic changes of adhering bacteria & dec cell adhesion. • PEMF creates unbalanced population thus reducing H. pylori’s ability to protect itself.

  17. Antitumor Effect & PEMF Therapy • PEMF in melanoma model mice sig ↓ tumor weight vs controls. • TNF-alpha was sig ↑ in PEMF group. • PEMF slowed growth of T-cell lymphoma & prolonged survival. • Synergizing antitumor effect with PEMF +suboptimal doxorubicin dose.

  18. PEMF and Osteoporosis

  19. PEMF Physiologic Effects • Increases bone mineral density. • Increases growth of osteoblasts. • Increases TGF-beta 1 (growth factor). • Decreases IL-6 (inflammatory cytokine). • Decreases PGE-2 (prostaglandin). • Lowers urinary deoxypyridinoline (uDPD).

  20. Urinary Deoxypyridinoline (uDPD) • DPD cross-links Type I collagen. • uDPD measure of bone resorption. • ↑ levels indicate active bone loss. • Easy to measure spot AM urine. • Recheck within 30-90 days. • Covered by Medicare.

  21. Osteoporosis Case Studies

  22. PEMF/Osteoporosis Case Study #1 66 y.o ♀ with osteoporosis (T-score -3.1) • Baseline uDPD 9.7 nMCr (NL <6.5) • Weekly 1 hour PEMF sessions x 2 months • At 2 months, uDPD 4.5 (53.61% drop!) • Maintenance monthly 1 hour PEMF sessions • At 6 months, uDPD 5.5 • At 9 months, uDPD 4.5

  23. Case Study #1 Urine DPD

  24. PEMF/Osteoporosis Case Study #2 63 y.o. ♀ osteoporosis (T-score LS -4.1) • Baseline uDPD 9.7 nMCr (NL < 6.5) • Monthly 1 hour PEMF sessions x 4 months • Weekly 1 hour PEMF sessions x 6 months • 2-3 x weekly PEMF sessions x 3 weeks • At 6 months, uDPD 5.0 (48.5% drop!)

  25. Case Study #2 Urine DPD

  26. PEMF/Osteoporosis Case Study #3 62 y.o. ♀ with osteoporosis (T-score -2.6) • Baseline uDPD 8.9 nMCr (NL < 6.5) • Eight 30 minute PEMF session over 3 weeks • At 3 weeks, uDPD 6.6 (25.84% drop!)

  27. Case Study #3 Urine DPD

  28. Conclusion • Biological systems ⇔ dynamic EM entity. • PEMF beneficial effects from bone to brain. • PEMF provides intelligent information. • Before any physiologic repair response, there must be an exchange of energy (information). • PEMF promotes this exchange in ailing tissue.

  29. Contact Information Keith R. Holden, M.D. 822 A1A North, Suite 310 Ponte Vedra Beach, FL 32082 (904) 473-4954 krholden@gmail.com www.Dr-Holden.com

More Related